We discover and develop novel proprietary therapeutics for the treatment of cancers, autoimmune & ophthalmologic diseases.
We leverage our novel proprietary Single Domain Antibody (sdAb) disruptive technology platform to provide us the advantages of a biologic & small molecule in the application of a number of diseases.
Using our proprietary platform we have developed single domain antibody’s (sdAbs) that specifically & selectively target intracellular proteins like STAT3 (signal transducer and activator of transcription 3), KRAS, and TNF-alpha.
Singh Biotechnology (SBT) is a biotechnology organization that is in the business of discovering and developing unique and propriety therapeutic agents for the treatment of a variety of diseases (cancers, autoimmune, and ophthalmologic diseases) by leveraging our novel technology platform.
At Singh Biotechnology we use our novel proprietary disruptive technology single domain antibody (sdAb) platform to create miniature antibodies that comprise solely of the variable region and therefore the sdAb is devoid of light chains. Using our proprietary technology we have engineered our sdAbs to be specific & bi-specific, with the ability to cross the cell membrane as well as the blood brain barrier (BBB) to specifically & selectively target intracellular proteins which play an important role in the pathogenesis of a variety of diseases.
The United States Food and Drug Administration (FDA) granted orphan drug designation to Singh Biotechnology for its novel anti-STAT3 B VHH13 single domain antibody (sdAb) SBT-100: